Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 peginterferon lambda-1a trial in chronic hepatitis D
2021-003665-35Phase 3Terminated
- Sponsor
- Eiger BioPharmaceuticals, Inc.
- Start
- Oct 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon lambda-1a in hepatitis D (HDV) (2 arms), sponsored by Eiger BioPharmaceuticals, Inc. Primary endpoint: HDV RNA below lower limit of quantification at post-treatment assessment. Started Oct 2021; status: terminated.
02
Drugs
peginterferon lambda-1a
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on 2021-003665-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003665-35.